(Total Views: 610)
Posted On: 05/01/2022 11:41:47 PM
Post# of 154011
Doesn't hold any water, this argument because the share price went back up in Feb 2021 to 6.70, HIV was no longer the play, nobody cared about HIV, only about how LL was going to do in CD12.
But I was already around since Sep 2019 for HIV, so Amarex had already failed at least twice in their job. We should have had a BLA before the Montefiore Covid success.
If you are really a shareholder why aren't you posting about NASH or a Long Hauler partner. The new Long Hauler CCR5 news about a new look at the pathology is really exciting. This email thing is a bloody bore.
But I was already around since Sep 2019 for HIV, so Amarex had already failed at least twice in their job. We should have had a BLA before the Montefiore Covid success.
If you are really a shareholder why aren't you posting about NASH or a Long Hauler partner. The new Long Hauler CCR5 news about a new look at the pathology is really exciting. This email thing is a bloody bore.
(5)
(0)
